7 Financial Red Flags That Kill a Startup's Series A Before It Starts

7 Financial Red Flags That Kill a Startup's Series A Before It Starts

Institutional investors don't kill deals because the product is bad. They kill deals because the books can't support the narrative the founder is telling.

Series A diligence is ruthless. A lead investor at a reputable fund will spend 4-6 weeks pulling apart your financials before the term sheet becomes binding. What they find in that process either confirms the valuation or gives them the leverage to reprice — or just walk. Most of these problems aren't fraud. They're the predictable result of early-stage companies running on QuickBooks with no one who's seen a real diligence process.

Here are seven financial problems that kill or delay Series A rounds, with specific detail on why each one matters.

1. Cash-Basis Books Require an Accrual Restatement That Takes 4-8 Weeks and Signals Risk

Every institutional investor requires audited or reviewed GAAP financials, which means accrual basis. If your books are cash-basis — common for early-stage companies — you need a full restatement before diligence can close.

That restatement takes 4-8 weeks in the best case. During that window, the investor's enthusiasm cools, competing deals get looked at, and founders often make concessions they wouldn't have otherwise made. The investor who found the gap now knows the company's financial infrastructure isn't ready for institutional oversight — which is exactly the thing a Series A is supposed to enable. The fix is straightforward: move to accrual before you start raising. Don't wait for a term sheet to discover the problem.

2. Cash-Basis Revenue Recognition Makes ARR Look 20-30% Larger Than It Actually Is

Enterprise SaaS companies often look much healthier on a cash basis than on accrual. A $500,000 upfront annual contract recognized in full at signing looks like a great Q1. On accrual under ASC 606, it's $125,000 per quarter.

The delta matters to investors because they're valuing the business on a multiple of ARR — and that multiple gets applied to the number in your deck, which they'll immediately test against your restated books. If your $4M ARR turns into $3.1M ARR after deferred revenue, unearned contracts, and unbilled adjustments are stripped out, the valuation conversation changes in a direction that doesn't favor you. Get the restatement done before you know what the multiple looks like. Finding out during diligence means you're negotiating from behind.

3. Cap Table Discrepancies Stop Diligence Cold

SAFEs convert at the next qualified financing. Convertible notes convert at the next qualified financing. Option grants vest on schedules. None of this automatically shows up in your general ledger — and investors will verify your cap table model against both your legal documents and your GL.

If there are SAFEs outstanding that don't appear in your equity rollforward, or option grants that aren't reflected in your stock-based compensation expense, diligence stops until it's reconciled. This isn't a minor administrative issue. A cap table discrepancy raises questions about the company's record-keeping competence and, occasionally, about whether shares have been promised informally to people not on the formal cap table. Clean this up quarterly, not on the eve of a raise.

4. No Board-Approved Financial Statements Signal Weak Governance

Institutional investors expect that your historical financials have been reviewed by someone other than the founder who prepared them. Board-approved financials — even informal ones from an active seed-stage board — demonstrate that there's governance in place.

A founder who is both the CFO and the only person who signs off on financials is presenting inherently unverified data. That doesn't mean the numbers are wrong. It means there's no mechanism to know whether they're right. Sophisticated investors discount the historical data accordingly. If you don't have a finance-focused board member or a formal audit committee, at minimum your outside accountant should be presenting monthly financials to the board for approval before you go into a raise.

5. Related-Party Transactions Without Documentation Are an Automatic Repricing Event

Founder loans to the company. Personal expenses expensed through the business. A family member on payroll for a role that doesn't seem to exist. These are common at the seed stage and not inherently disqualifying — but they need documentation that survives scrutiny.

An investor who finds an undocumented $150,000 loan from a founder to the company, or $40,000 in personal travel run through G&A, or a spouse on payroll at $80,000 with no apparent function, is now doing a different kind of math. Not just "how profitable is this business" but "what else is in here that I don't know about." Related-party transactions need to be at arm's length, documented, disclosed in footnotes, and approved by the board. The ones that aren't will be found — and found during the worst possible time.

6. Section 174 R&D Capitalization Exposure Creates a Deferred Tax Liability That Surprises Everyone

This one is almost universally missed at seed-stage companies. Since 2022, IRC §174 requires domestic research and experimental expenses to be capitalized and amortized over 5 years rather than deducted in full. Companies that have been expensing software development costs fully in the year incurred have been creating a deferred tax liability they may not have recorded.

During diligence, a sophisticated investor's tax advisor will flag this. The exposure can be significant — a company spending $1M per year on domestic development has been over-deducting by $800,000/year, which means there's a cumulative deferred liability sitting unrecorded on the balance sheet. That's not disqualifying, but it changes the net asset calculation and occasionally surfaces in representations and warranties. Know your §174 exposure before someone else quantifies it for you.

7. Books 60+ Days Behind Signal That the Company Isn't Ready to Operate at Scale

An investor who asks for your last three months of financials and gets them two weeks later has learned something important: this company can't produce financial information on demand.

Series A companies are expected to have a CFO or VP Finance in place within 12-18 months of closing. They're expected to close books monthly within 15 days. They're expected to produce a board package quarterly that includes actuals vs. budget variance analysis. If you can't produce financials within 48 hours during diligence — one of the most financially scrutinized periods in the company's history — the investor is already doing the math on what it's going to cost to build the infrastructure they need. Some walk. Some build it into the post-money use-of-funds but price the pre-money down accordingly.

Close your books monthly. Make it a habit before the raise, not a scramble during it.

Fix These Before the Term Sheet

Every one of these problems is fixable. The issue is timing. Fixed before you start raising, they're routine housekeeping. Found by an investor during diligence, they're negotiating leverage.

Ursa Consultants specializes in getting venture-backed companies' financials Series A-ready — accrual conversion, cap table reconciliation, board reporting infrastructure, and §174 analysis included.

Find Ursa Consultants on Sam's List

General information only, not legal or tax advice. Consult a qualified professional for your specific situation.